RAPT Therapeutics' (RAPT) Hold Rating Reaffirmed at Stifel Nicolaus

RAPT Therapeutics (NASDAQ:RAPT - Get Free Report)'s stock had its "hold" rating reiterated by equities research analysts at Stifel Nicolaus in a research report issued on Wednesday, MarketBeat.com reports. They currently have a $2.00 price objective on the stock, down from their prior price objective of $7.00. Stifel Nicolaus' price objective would suggest a potential upside of 27.39% from the company's previous close.

Several other equities research analysts have also commented on RAPT. Wells Fargo & Company lowered their price objective on RAPT Therapeutics from $17.00 to $4.00 and set an "overweight" rating on the stock in a research report on Tuesday. HC Wainwright reissued a "neutral" rating on shares of RAPT Therapeutics in a report on Tuesday. JPMorgan Chase & Co. lowered shares of RAPT Therapeutics from a "neutral" rating to an "underweight" rating in a research report on Monday. Piper Sandler downgraded shares of RAPT Therapeutics from an "overweight" rating to a "neutral" rating and decreased their price objective for the stock from $8.00 to $2.00 in a research report on Monday. Finally, UBS Group dropped their target price on RAPT Therapeutics from $10.00 to $2.00 and set a "neutral" rating on the stock in a research report on Monday, September 9th. One investment analyst has rated the stock with a sell rating, ten have issued a hold rating and two have given a buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $13.00.

RAPT Therapeutics Stock Down 9.8 %

Shares of RAPT stock traded down $0.17 on Wednesday, hitting $1.57. The company had a trading volume of 1,169,149 shares, compared to its average volume of 756,071. The firm has a market cap of $54.79 million, a P/E ratio of -0.56 and a beta of 0.33. RAPT Therapeutics has a twelve month low of $1.31 and a twelve month high of $27.35. The company has a 50-day moving average price of $1.97 and a 200-day moving average price of $3.06.

Hedge Funds Weigh In On RAPT Therapeutics

Hedge funds have recently made changes to their positions in the company. Los Angeles Capital Management LLC raised its position in shares of RAPT Therapeutics by 138.1% in the third quarter. Los Angeles Capital Management LLC now owns 201,439 shares of the company's stock valued at $405,000 after buying an additional 116,853 shares during the last quarter. Exchange Traded Concepts LLC raised its holdings in RAPT Therapeutics by 244.7% in the 3rd quarter. Exchange Traded Concepts LLC now owns 89,076 shares of the company's stock valued at $179,000 after acquiring an additional 63,235 shares during the last quarter. Point72 Asset Management L.P. raised its holdings in RAPT Therapeutics by 176,725.0% in the 2nd quarter. Point72 Asset Management L.P. now owns 707,300 shares of the company's stock valued at $2,157,000 after acquiring an additional 706,900 shares during the last quarter. AQR Capital Management LLC purchased a new position in RAPT Therapeutics in the 2nd quarter worth approximately $270,000. Finally, Squarepoint Ops LLC acquired a new position in shares of RAPT Therapeutics during the 2nd quarter worth approximately $329,000. Institutional investors and hedge funds own 99.09% of the company's stock.

About RAPT Therapeutics

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.